Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
06/2000
06/28/2000EP1011635A1 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
06/28/2000CN1258290A Salt
06/28/2000CN1258283A Cyclic diamine compounds and medicine contg. same
06/28/2000CN1258218A Mixture of primary fatty acids obtained from sugar can wax and pharmaceutical use thereof
06/28/2000CN1257864A Imidazoline compound, preparing process thereof and pharmaceutical composition contg. same
06/28/2000CN1257731A Full-function nutrients for tube-fed patients and its preparing process
06/28/2000CN1257707A Health-care medicine for improving vitality of old people and its prescription
06/28/2000CN1053826C Tonic hypoglycemic capsule and preparing process thereof
06/28/2000CN1053811C Fat-eliminating tincture
06/28/2000CN1053807C Vitamin E drop
06/28/2000CA2293088A1 Method and composition for masking taste and odor from fish oil
06/27/2000US6080786 Solid compositions suitable for oral administration comprising L-carnitine or alkanoyl-L-carnitine choline tartrate
06/27/2000US6080778 Methods for decreasing beta amyloid protein
06/27/2000US6080774 Substituted biphenylsulfonamide endothelin antagonists
06/27/2000US6080765 Pharmaceutical composition
06/27/2000US6080764 Superoxide radical inhibitor
06/27/2000US6080754 For treatment and prophylaxis of estrogen related syndromes and disorders
06/27/2000US6080721 Pulmonary delivery of active fragments of parathyroid hormone
06/27/2000US6080402 Immobilization of lipases by entrapment in silica matrices
06/27/2000CA2198564C Method of reducing tissue damage associated with non-cardiac ischemia
06/22/2000WO2000036105A1 Prostacyclin-stimulating factor-2
06/22/2000WO2000036104A1 Pancreatic polypeptide zsig66
06/22/2000WO2000035952A2 Compounds for control of eating, growth and body weight
06/22/2000WO2000035948A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000WO2000035946A1 Methods
06/22/2000WO2000035939A2 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035937A1 47 human secreted proteins
06/22/2000WO2000035936A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000WO2000035922A1 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists
06/22/2000WO2000035915A1 Piperazine derivatives
06/22/2000WO2000035911A1 Heteroaryl-cyclic acetals
06/22/2000WO2000035910A1 Derivative of paroxetine
06/22/2000WO2000035907A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000WO2000035892A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
06/22/2000WO2000035891A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000WO2000035882A1 1,2,3,4-tetrahydronaphthalenes and their pharmaceutical use
06/22/2000WO2000035878A1 1,4-piperazine derivatives having 5ht1a receptor activity
06/22/2000WO2000035875A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000WO2000035874A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000WO2000035867A1 Novel ligands of nuclear receptor
06/22/2000WO2000035855A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000WO2000035848A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000WO2000035444A1 USE OF η-TOCOPHEROL AND ITS OXIDATIVE METABOLITE LLU-α IN THE TREATMENT OF DISEASE
06/22/2000WO2000035430A2 Homer a new target of treating psychiatric disorders
06/22/2000WO2000035425A1 STABLE PHARMACEUTICAL FORMULATION COMPRISING A HMG-CoA REDUCTASE INHIBITOR
06/22/2000WO2000035280A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000WO2000035279A1 Exo-s-mecamylamine formulation and use in treatment
06/22/2000WO2000012703A3 Protein transport-associated molecules
06/22/2000WO2000012544A3 Novel irap-bp polypeptide and nucleic acid molecules and uses therefor
06/22/2000WO2000011029A3 Novel anti-diabetic peptides
06/22/2000WO2000007624A3 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix
06/22/2000WO1999048488A3 Methods for decreasing beta amyloid protein
06/22/2000WO1999038504A8 Pharmaceutical uses of optically pure (-)-bupropion
06/22/2000CA2393442A1 Exo-r-mecamylamine formulation and use in treatment
06/22/2000CA2362423A1 47 human secreted proteins
06/22/2000CA2355363A1 Prostacyclin-stimulating factor-2
06/22/2000CA2355299A1 Novel ligands of nuclear receptor
06/22/2000CA2355211A1 Aldose reductase inhibitors and pharmaceutical compositions
06/22/2000CA2355202A1 Imidazolones and their use in treating benign prostatic hyperplasia and other disorders
06/22/2000CA2355201A1 Morpholinone and morpholine derivatives and uses thereof
06/22/2000CA2355039A1 Pancreatic polypeptide zsig66
06/22/2000CA2354875A1 Piperazine derivatives
06/22/2000CA2354456A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354422A1 Connective tissue growth factor fragments and methods and uses thereof
06/22/2000CA2354323A1 Homer a new target of treating psychiatric disorders
06/22/2000CA2354061A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5ht1a receptor activity
06/22/2000CA2352570A1 Methods and compositions for treating disorders involving excitotoxicity
06/22/2000CA2351860A1 Piperazine ethylamide derivatives with 5-ht1a receptor activity
06/22/2000CA2351859A1 1,4-piperazine derivatives having 5ht1a receptor activity
06/22/2000CA2351464A1 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
06/22/2000CA2351400A1 Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine urea derivatives having 5ht1a receptor activity
06/22/2000CA2351385A1 2,3,4,4a-tetrahydro-1h-pyrazino(1,2-a)quinoxalin-5(6h)one derivates being 5ht2c agonists
06/21/2000EP1010694A2 Spiroimidazoline derivatives and their use as alpha2-adrenergic antagonists and monoamines-reuptake blockers
06/21/2000EP1010693A1 Imidazoline derivatives, preparation and pharmaceutical compositions containing them
06/21/2000EP1010691A2 Hydrazide derivatives, process for their preparation and pharmaceutical compositions containing them
06/21/2000EP1010424A1 Liver fat accumulation inhibitory composition, food additive for liver fat accumulation inhibition, and method of inhibiting liver fat accumulation
06/21/2000EP1009829A1 Adipocyte-specific protein homologs
06/21/2000EP1009822A1 Antisense treatment of pulmonary hypertension
06/21/2000EP1009770A1 Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
06/21/2000EP1009752A1 Novel molecules of the tango-77 related protein family and uses thereof
06/21/2000EP1009743A1 Certain benzothiazine dioxide endothelin antagonists and processes for their preparation
06/21/2000EP1009738A1 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors
06/21/2000EP1009400A1 Combination therapy comprising atorvastatin and an antihypertensive agent
06/21/2000EP1009377A1 Medical uses of pyruvates
06/21/2000EP1009232A1 Methods for treating insulin resistance and identifying patients at risk for the disease
06/21/2000DE19858789A1 Medicament combination of cerivastatin and fibrate, has additive effect in the treatment of lipid metabolism disorders, e.g. dyslipidemia or atherosclerosis
06/21/2000DE19858463A1 Verwendung eines Fibrinklebers zur Regeneration des Lebergewebes Use of fibrin glue for the regeneration of liver tissue
06/21/2000CN1257538A Short peptides which selectively modulate the activity of serine/threonine kinases
06/21/2000CN1257501A Process for preparing 6-0-monoesters of castanospermine
06/21/2000CN1257499A 8-Azabicyclo (3,2,1) oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ACH receptors
06/21/2000CN1257474A New nitromethyl ketones, process for preparing them and compositions containing them
06/21/2000CN1257430A Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
06/21/2000CN1053662C New tricyclic amide compounds, processes for their preparation and the pharmaceutical compositions containing same
06/21/2000CN1053583C Medicine for treating diabetes mellitus and preparation process thereof
06/20/2000US6077846 Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
06/20/2000US6077829 Comprising brain derived neurotrophic factor(bdnf), polyoxyethylene sorbitan monooleate as nonionic surfactant, and carrier; prevents denaturing and polymerization of bdnf; storage stability
06/20/2000US6077828 Method for the prevention and treatment of cachexia and anorexia
06/20/2000CA2198536C Method of reducing tissue damage associated with ischemia
06/20/2000CA2001618C Gestodene-containing agent for transdermal administration
06/18/2000CA2292481A1 Use of fibrin adhesive for tissue regeneration
1 ... 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 ... 1298